Joshua Schiff

Prostate-specific Antigen Response and Eradication of Androgen Receptor Amplification with High-dose Testosterone in Prostate Cancer

Metastatic castrate-resistant prostate cancer (CRPC) has been studied from a tissue-based molecular perspective [1] and much has been learned. Alterations in the androgen receptor (AR) are common, as are a multiplicity of other genetic changes. More recent studies indicate that plasma cell-free DNA (cfDNA) may be used to assess the molecular genetics of tumors, and potentially direct therapy [2]. Resistance to newer hormonal agents such as abiraterone and enzalutamide can be predicted by cfDNA changes, including both AR amplification and select AR mutations [3,4]. Here we describe a case involving a heavily pretreated patient for whom